Meloxicam
Product Images NDC 42549-513

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 42549-513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by 4uortho Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panelndc: 42549-512-28gabapentin 100mg #28 Capsule(s) (Gabapentin 100mg 42549 Label)

Label for Gabapentin 100mg capsules, with 60 capsules per container. The label identifies the product as a generic for Neurontin and includes the NDC code 42549-512-60. It is packaged and distributed by STAT RX USA in Gainesville, GA, and distributed by Amneal Pharmaceuticals in Glasgow, KY. The label includes warnings to keep out of reach of children.*

FDA Label Image

Principal Display Panelndc: 42549-513-28gabapentin 300mg #28 Capsule(s) (Gabapentin 300mg 42549 Label)

Packaging label for Gabapentin 300 mg capsules, containing 28 capsules. The label shows it is a generic for Neurontin with NDC 42549-513-28. Distributed by STAT USA in Gainesville, GA, and packed by Amneal Pharmaceuticals in Glasgow, KY. The label includes storage instructions and a sample lot number.*

FDA Label Image

Structural Formula Of Gabapentin (Gabapentin 1)

Chemical structure diagram of Meloxicam, showing its molecular framework with a thiazole ring and carboxymethyl and aminomethyl side groups.*

FDA Label Image

Dc2d0eb8-figure-02 (Gabapentin 2)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The Gabapentin group shows a marked decrease in mean pain score compared to placebo, with statistical significance indicated.*

FDA Label Image

Dc2d0eb8-figure-03 (Gabapentin 3)

A line graph depicting mean pain score over an 8-week period for two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis indicates mean pain score ranging from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period and notes statistical significance at p < 0.01.*

FDA Label Image

Dc2d0eb8-figure-04 (Gabapentin 4)

A bar chart illustrating the percentage of responders at endpoint from two studies comparing Meloxicam and placebo. Study 1 shows responder percentages for placebo (12%) and Meloxicam (29% at 3600 dose). Study 2 shows placebo (14%) and Meloxicam responder percentages at 1800 (32%) and 2400 (34%) doses. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Dc2d0eb8-figure-05 (Gabapentin 5)

A scatter plot comparing percentage difference versus daily dose in milligrams for three studies labeled a, b, and c. The x-axis shows daily doses ranging from 600 to 1800 mg, while the y-axis indicates percentage difference from 2% to 22%. Data points for each study are distinguished by different fill patterns.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.